BMS’ MS pill gets funding in Scotland after rejection in England by NICEScotland’s drugs cost-effectiveness body has recommended Bristol-Myers Squibb’s Zeposia multiple sclerosis pill, setting a potential north-south access divide Share XBMS’ MS pill gets funding in Scotland after rejection in England by NICEhttps://pharmaphorum.com/news/bms-ms-pill-gets-funding-in-scotland-after-rejection-in-england-by-nice/
Scotland backs Roche’s Rozlytrek for ROS1 lung cancerThe Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of Share XScotland backs Roche’s Rozlytrek for ROS1 lung cancerhttps://pharmaphorum.com/news/scotland-backs-roches-rozlytrek-for-ntrk-tumours/
Scotland says no to Daiichi Sankyo’s cholesterol drug NilemdoThe Scottish Medicines Consortium (SMC) has rejected Daiichi Sankyo’s new cholesterol-lowering drug Nilemdo for use by NHS Scotland, Share XScotland says no to Daiichi Sankyo’s cholesterol drug Nilemdohttps://pharmaphorum.com/news/scotland-says-no-to-daiichi-sankyos-cholesterol-drug-nilemdo/
After NICE okay, Scots denied access to Vifor’s VeltassaThe Scottish Medicines Consortium (SMC) has ruled that there’s not enough evidence to support NHS funding of Vifor Share XAfter NICE okay, Scots denied access to Vifor’s Veltassahttps://pharmaphorum.com/news/after-nice-okay-scots-denied-access-to-vifors-veltassa/
How does HTA for orphan drugs differ across Europe?New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines Share XHow does HTA for orphan drugs differ across Europe?https://pharmaphorum.com/views-analysis-market-access/how-does-hta-for-orphan-drugs-differ-across-europe/
Novartis’ Kymriah okayed for funding in Scotland for lymphomaNovartis’ Kymriah has become the first CAR-T available to NHS patients across the UK after Scotland’s medicines cost-effectiveness Share XNovartis’ Kymriah okayed for funding in Scotland for lymphomahttps://pharmaphorum.com/news/novartis-kymriah-okayed-for-funding-in-scotland-for-lymphoma/
Scotland backs Pfizer’s Ibrance for breast cancerPfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced Share XScotland backs Pfizer’s Ibrance for breast cancerhttps://pharmaphorum.com/news/scotland-backs-pfizers-ibrance-for-breast-cancer/
SMC approves medicines for breast cancer, skin cancer, schizophreniaThe Scottish Medicines Consortium (SMC) has given approvals to Lilly’s breast cancer drug Verzenios, Merck’s Keytruda and Allergan’s Share XSMC approves medicines for breast cancer, skin cancer, schizophreniahttps://pharmaphorum.com/news/smc-approves-medicines-for-breast-cancer-skin-cancer-schizophrenia/
Keeping up the PACE at the Scottish Medicines Consortium (SMC)There are many ways that patient centricity could be delivered when doing a health technology assessment (HTA). The Share XKeeping up the PACE at the Scottish Medicines Consortium (SMC)https://pharmaphorum.com/views-analysis-market-access/keeping-up-the-pace-at-the-scottish-medicines-consortium-smc/
